Group 1 - Baoti shares: The controlling shareholder has increased its stake by 1.004% [1] - Chengda Pharmaceutical: Qianhai Shengtai plans to reduce its holdings by 7.27% [1] - Huawu Co., Ltd.: Nie Jinghua and others plan to reduce their holdings by no more than 3% within three months [1] Group 2 - Changjiang Materials: The controlling shareholder plans to reduce its holdings by no more than 3% [1] - Weishi Electronics: The controlling shareholder's reduction plan does not exceed 3% [1] - Jialian Technology: A related party plans to reduce its holdings by 2.6166% within three months [1] Group 3 - Funeng Technology: Shareholders plan to reduce their holdings by no more than 2% [1] - Lanfeng Biochemical: Hainan Wenqin reduced its holdings by 2.00% [1] - Koweil: Shareholders Jingkun Investment and Hetu Investment plan to reduce their holdings by no more than 2.34% [1] Group 4 - Huayin Power: Hunan Energy plans to reduce its holdings by 1% [1] - Bid Pharmaceutical: Zhoushan Xinxin plans to reduce its holdings by 1.00% [1] - Guanhao High-tech: Shareholder Yuechuang Investment plans to reduce its holdings by no more than 1% [1] Group 5 - Juxin Technology: Zhuhai Chenyour plans to reduce its holdings by no more than 0.5% [1] - Tianji Shares: Shantou Tianji reduced its holdings by 0.61% [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201) announced a plan for a significant share reduction by its shareholder Qianhai Shengtai Investment Enterprise (Limited Partnership) [1] - Qianhai Shengtai holds 11,006,900 shares, accounting for 7.27% of the company's total share capital after excluding repurchased shares [1] - The shareholder plans to reduce its holdings by up to 11,006,970 shares within three months after the announcement date, using centralized bidding or block trading methods [1]

Core Viewpoint - Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its shareholding in Chengda Pharmaceutical by up to 11,006,897 shares, representing 7.27% of the company's total share capital after excluding repurchased shares, within a three-month period starting from September 29, 2025 [1][2]. Shareholder Information - Shenzhen Qianhai Shengtai holds 11,006,897 shares, accounting for 7.27% of the total share capital, and the total share capital of the company is 154,713,824 shares, with 151,469,124 shares after excluding repurchased shares [2]. - The reduction is due to the shareholder's operational needs, and the shares were acquired prior to the company's initial public offering and through capital reserve conversion [2]. Reduction Plan Details - The reduction will occur through centralized bidding or block trading, with a planned period from September 29, 2025, to December 28, 2025 [1][2]. - The reduction price will be determined based on market conditions, and adjustments will be made if there are changes in share capital during the reduction period [2]. Shareholder Commitment - The shareholder has provided commitments regarding the lock-up of shares and intentions for reduction, with no reductions made during the lock-up period [3].

Group 1 - The core point of the article is that Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), a shareholder holding 11,006,900 shares (7.27% of the total share capital after excluding repurchased shares) of Chengda Pharmaceutical (301201.SZ), plans to reduce its holdings within a specified timeframe [1] Group 2 - The planned reduction of shares will occur through centralized bidding or block trading methods [1] - The reduction period is set from September 29, 2025, to December 28, 2025 [1] - The maximum number of shares to be reduced is also 11,006,900, maintaining the same percentage of 7.27% of the total share capital after excluding repurchased shares [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201) announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its stake by up to 11,006,900 shares, which represents 7.11% of the company's total share capital, within three months after 15 trading days [1] Group 2 - The reduction will be executed through centralized bidding or block trading methods [1] - The announcement was made on the evening of September 5 [1] - The shareholder currently holds a 7.11% stake in the company [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) announced that its shareholder, Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), plans to reduce its holdings by up to 11,006,900 shares within three months after 15 trading days from the announcement date, which represents 7.27% of the total share capital excluding repurchased shares [1]

Core Viewpoint - Chengda Pharmaceutical (301201) announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings of 11.0069 million shares, representing 7.27% of the company's total share capital after excluding repurchased shares, within three months from September 29, 2025, to December 28, 2025, through centralized bidding or block trading [1] Summary by Relevant Sections - Shareholder Reduction Plan - Shenzhen Qianhai Shengtai Investment Enterprise intends to reduce its stake by up to 11.0069 million shares [1] - This reduction accounts for 7.27% of the company's total share capital after excluding repurchased shares [1] - The planned reduction period is from September 29, 2025, to December 28, 2025 [1] - Trading Method - The shares will be sold through centralized bidding or block trading methods [1]

Group 1 - The major shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its stake in Chengda Pharmaceutical from September 29, 2025, to December 28, 2025 [1] - The planned reduction involves selling up to 11.0069 million shares, which represents 7.27% of the company's total share capital after excluding repurchased shares [1] - The selling price will be determined based on market conditions [1]

证券代码：301201 证券简称：诚达药业 公告编号：2025-033 诚达药业股份有限公司 关于持股 5%以上股东减持股份的预披露公告 持股 5%以上股东深圳前海晟泰投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有诚达药业股份有限公司（以下简称"公司"、"发行人"）股份 11,006,897 股（占本公司剔除回购专户股份数后总股本比例 7.27%）的股东深圳 前海晟泰投资企业（有限合伙）计划在本公告披露之日起 15 个交易日后的 3 个 月内（2025 年 9 月 29 日至 2025 年 12 月 28 日）以集中竞价或大宗交易方式减 持本公司股份不超过 11,006,897 股（占本公司剔除回购专户股份数后总股本比 例 7.27%）。 2、根据《上市公司创业投资基金股东减持股份的特别规定》及《深圳证券 交易所上市公司创业投资基金股东减持股份实施细则》中关于创业投资基金投资 符合条件的企业的相关规定，深圳前海晟泰投资企业（有限合伙）（以下简称"前 海晟泰"）满足相 ...

格隆汇8月27日｜近日，成都施贝康生物医药科技有限公司（简称"施贝康"）宣布完成B轮融资。本轮 融资由上市公司诚达药业独家战略投资，融资资金将主要用于加快研发管线建设、扩建研发实验室，并 推动核心产品的国际化申报进程。据施贝康介绍，此前，其在创业早期还获得复星医药、川创投等产业 投资方和本地投资机构的投资布局。 ...